Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.autrev.2020.102594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study.
Clin Rheumatol
December 2024
Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Str 17, Hefei, 230001, Anhui, China.
Objective: To examine the effectiveness and safety of two different B cell activating factor/proliferation-inducing ligand inhibitors, telitacicept and belimumab, in treating patients with active systemic lupus erythematosus (SLE).
Methods: Patients with active SLE who received belimumab (n = 100) or telitacicept (n = 101) from 2019 to 2023 at multiple centers in China were retrospectively collected, and the effectiveness and safety of telitacicept and belimumab was evaluated. The subgroups of lupus nephritis and hematologic abnormalities were analyzed to explore if there were any differences in the efficacy of the two biologics on improving kidney and blood systems.
Infections in Sjögren's disease: a clinical concern or not?
Clin Exp Rheumatol
December 2024
Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens; and Laboratory of Immunobiology, Centre for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece.
Patients with autoimmune diseases are particularly prone to infections due to both the underlying immune dysfunction and the use of immunosuppressive therapies. Sjögren's disease (SjD) serves as a valuable model for studying the complex interplay between autoimmunity and infections. This review focuses on the infection risks associated with SjD, emphasising key areas such as oral, respiratory, and urogenital infections, along with complications arising from systemic infections.
View Article and Find Full Text PDFEarly decrease of T-bet B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients.
Immunol Lett
December 2024
Lupus Clinic, Rheumatology, Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Viale del Policlinico 155 00161 Rome, Italy.
Systemic lupus erythematosus (SLE) is characterized by B cell dysregulation and expansion of atypical B cells that may correlate with disease manifestations and activity. This study investigated the impact of subcutaneous (sc) Belimumab (BLM) on the peripheral B cell compartment and on the functional properties of CD21, T-bet and CD11c atypical B cells, in 21 active SLE patients over a 12-month period. At baseline, active SLE patients displayed reduced unswitched IgM memory B cells and expansion of atypical B cells, compared to healthy donors and to SLE patients in remission.
View Article and Find Full Text PDFDisease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE.
Nat Immunol
November 2024
Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.
Severe acute respiratory syndrome coronavirus 2 mRNA vaccination has reduced effectiveness in certain immunocompromised individuals. However, the cellular mechanisms underlying these defects, as well as the contribution of disease-induced cellular abnormalities, remain largely unexplored. In this study, we conducted a comprehensive serological and cellular analysis of patients with autoimmune systemic lupus erythematosus (SLE) who received the Wuhan-Hu-1 monovalent mRNA coronavirus disease 2019 vaccine.
View Article and Find Full Text PDFMolecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.
Ann Rheum Dis
November 2024
Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy, Athens, Greece
Article Synopsis
- The study investigates how belimumab, a drug for systemic lupus erythematosus (SLE), affects blood gene expression and whether early treatment response can be predicted through blood tests.
- RNA sequencing was conducted on blood samples from 45 active SLE patients before and after 6 months of treatment, revealing significant changes in gene expression related to immune cell activity and disease severity.
- Results indicate that belimumab reduces specific immune pathways and may reverse disease markers, with a model predicting treatment response based on 50 genes showcasing 84% accuracy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!